Abstract 192P
Background
Experimental and clinical studies have shown an increase in the level of interleukin-6 (IL-6) in the blood plasma and other cytokines in obstructive jaundice. The combination of a persistent increase in cytokines and an extended acute response phase is associated with a decrease in protein calories, leading to surgical complications and death.
Methods
The study involved 41 patients treated at the Gastroenterology department in 1st Republic Clinic, Tashkent aged from 33 to 84 years old (62.8 ± 2.14) were studied, of whom 26 (63.4%) were men and 15 (36.6%) were women. The duration of the icteric period by the time of admission to the hospital averaged 28.7 ± 2.18 days. At the same time, in 6 (14.6%) patients the duration of cholestasis was up to 15 days, in 10 (24.4%) - from 15 to 30 days, in 25 (61.0%) - more than 1 month. Percutaneous transhepatic cholangiography (PTCH) with per-cutaneous transhepatic cholangiostomy (PTCHS) was performed for all patients, regardless of the localization of the tumor process. The level of IL-6 in serum and bile was determined by ELISA method.
Results
The concentration of IL-6 before the overlap of PTCH in the serum was higher than normal, averaging 152.65 ± 16.3 pg/ml. Immediately after the overlaying of PTCH in bile, this indicator was on average 68.58 ± 7.24 pg/ml. The high content of IL-6 in serum and bile testified to a pronounced endogenous intoxication of the body. The concentration of IL-6 in the initial day after the imposition of PTCH in serum decreased to 32.9%. In the following days, this indicator remained virtually unchanged, but on the 6th day of observation, there was a slight increase in his blood. In the bile at the same time, the concentration of IL-6 decreased by 17.1%. These indicators remained virtually unchanged up to 6 days of observation. On the 14th day, the decrease in the level of IL-6 in the blood compared to baseline was 64.4%, and in the bile 54.3% (P < 0.001).
Conclusions
Thus, the determination of IL-6 in the blood and in the bile makes it possible to more objectively evaluate the tumor process and the cytokine-induced endogenous intoxication to the response of the therapeutic measures taken in biliopancreatoduodenal tumors complicated by the mechanical jaundice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract